GlassScriptPhysician profile
Vishal Sawhney
NPI 1164622247
$49,496.43
in general payments reported to CMS, 2019-2025
52 companies · $2,344 in 2025
The $2,344 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $9,304 · 2021: $8,306 · 2022: $2,817 · 2023: $1,737 · 2024: $1,690 · 2025: $2,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,712 · Education: $58.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,711.85 |
| Education | $58.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22,325.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $16,823.93 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,131.16 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,066.45 | 2019-2025 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,018.92 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $609.55 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $513.19 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $489.02 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $450.82 | 2020-2025 | Glassia, Aralast |
| Mylan Specialty L.P. | $447.19 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $429.69 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $361.96 | 2019-2025 | Xolair |
| Insmed, INC. | $259.48 | 2022-2025 | Arikayce, Brinsupri |
| Amgen INC. | $226.17 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $212.97 | 2025 | Ohtuvayre |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $172.42 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $171.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $171.30 | 2019-2025 | Winrevair |
| Viatris Specialty LLC | $159.58 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $150.92 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $111.71 | 2019-2021 | |
| Harmony Biosciences LLC | $111.26 | 2020-2024 | Wakix |
| Electromed, INC. | $106.71 | 2022-2025 | Smartvest |
| Esperion Therapeutics, INC. | $98.89 | 2020 | |
| Alexion Pharmaceuticals, INC. | $94.24 | 2021-2024 | Ultomiris |
| Portola Pharmaceuticals, LLC | $84.85 | 2019-2020 | |
| Lilly USA, LLC | $54.91 | 2025 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $51.09 | 2024 | Inspire |
| Fisher & Paykel Healthcare INC | $50.81 | 2024 | Fisher & Paykel Healthcare |
| Shire North American Group INC | $44.13 | 2019 | |
| Astellas Pharma US INC | $44.07 | 2025 | Cresemba |
| Pulmonx Corporation | $42.83 | 2024-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Baxter Healthcare | $42.73 | 2022-2024 | Hillrom - Monarch Airway Clearance System |
| Novartis Pharmaceuticals Corporation | $42.26 | 2019-2020 | |
| Inogen, INC. | $41.54 | 2022 | |
| Ani Pharmaceuticals, INC. | $32.60 | 2025 | Purified Cortrophin Gel |
| Csl Behring | $27.30 | 2020 | |
| Circassia INC. | $24.65 | 2020 | |
| Ambu INC. | $21.27 | 2025 | |
| Mallinckrodt Hospital Products INC. | $19.90 | 2022 | |
| Inari Medical, INC. | $17.69 | 2020 | |
| Adma Biomanufacturing LLC | $15.03 | 2021 | |
| Philips North America LLC | $14.99 | 2020 | |
| Abbvie INC. | $14.83 | 2022 | |
| Advanced Respiratory, INC | $14.60 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.24 | 2024 | |
| Allergan, INC. | $13.75 | 2019 | |
| Hikma Pharmaceuticals USA | $13.50 | 2023 | Ryaltris |
| Optinose US, INC. | $13.47 | 2024 | |
| Phadia US INC. | $13.06 | 2021 | |
| Mayne Pharma Commercial LLC | $12.19 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Sawhney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.